Clinical trial · Interventional
Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population
Effect of Helicobacter Pylori Eradication on Gastric Cancer Prevention in Korea: a Randomized Controlled Clinical Trial
NCT02112214CI-TRIAL-00084113HELPERactive not recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to define the role of H. pylori eradication in the prevention of gastric cancer and its precursors in the context of a population-based endoscopic screening program.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Helicobacter Pylori Infection | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 10-day bismuth-based quadruple therapy | Drug | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Intervention group
- description
- 10-day bismuth-based quadruple therapy for H. pylori positive subjects
- interventionNames
- Drug: 10-day bismuth-based quadruple therapy
- type
- PLACEBO_COMPARATOR
- label
- Placebo group
- description
- Placebo for H. pylori positive subjects
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- The incidence of gastric cancer between the intervention and placebo groups
- timeFrame
- Up to 10 years After H. pylori eradication
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Men and women aged 40-65 who are invited to participate in the National Cancer Screening Program and receive upper endoscopy * Willingness to sign an informed consent form * Good health, as determined by medical history and physical examination at enrollment Exclusion Criteria: * Personal history of gastric cancer * Family history of gastric cancer in a first degree relative * Diagnosis and active treatment for other organ cancer except carcinoma in situ within 5 years * Current treatment for serious medical condition which could hinder participation (such as liver cirrhosis, renal failure, pulmonary dysfunction including COPD or asthma, or uncontrolled infection) * Inadequate cardiovascular function including (a) New York Heart Association class III or IV heart disease, (b) unstable angina or myocardial infarction history, (c) history of significant ventricular arrhythmia requiring medication with antiarrhythmics, and (d) history of cerebrovascular accident * Requirement for therapeutic anticoagulant therapy, aspirin * Gastric resections due to benign disease * H. pylori eradication therapy history * Mental incompetence to understand and sign informed consent * Alcoholism, drug abuse * Serious chronic diseases according to the evaluation of the study physician * Presence of a contraindication to the use of eradication treatment regimens * Inability to provide an informed consent * Pregnant or lactating women * Treatment required due to peptic ulcer, gastric cancer or esophageal cancer identified during the endoscopic examination
References
Publications (0)
Data not yet available
No reference posted for this study.